Vincent Rajkumar: Lenalidomide Remains Among Medicare’s Highest-Cost Drugs
Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in Rochester and Editor‑in‑Chief at Blood Cancer Journal, shared on X: “Twenty years after it was first approved for myeloma, lenalidomide…
Read the full articleYou might also wanna read
ProPublica Investigation Reveals How Drugmaker's Price Hikes Made a $0.25 Pill Cost Nearly $1,000
Podcast Episode · Paper Trail · June 11 · 41m
apple.co·23d ago
A Cancer Patient and Reporter Investigates Why Revlimid Costs as Much as an iPhone Per Pill
When I was diagnosed with cancer, I set out to understand why a single pill of Revlimid cost the same as a new iPhone. I’ve covered high dru
propublica.org·28d ago
Proposed NIH Budget Cuts Threaten HIV Breakthroughs Like Lenacapavir, Article Argues
Biomedical advances such as lenacapavir depend on years of publicly funded basic research
thinkglobalhealth.org·21d agoStudy of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy
Conditions : HIV Infections Interventions : Drug: Lenacapavir; Drug: Lenacapavir Tablet; Drug: Teropavimab; Drug: Zinlirvimab; Drug: Caboteg
Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens
Conditions : HIV-1-infection Interventions : Drug: Lenacapavir; Drug: Lenacapavir Tablet; Drug: Teropavimab; Drug: Zinlirvimab; Drug: SBR Sp
STAT+: Medicare takes another swing at 340B cuts to hospitals
Reducing Medicare payments for 340B drugs is the latest proposal focused on the hotly debated drug discount program.
Comments
Sign in to join the conversation.
No comments yet. Be the first.